Oncolytics Biotech, Inc. Common Shares (ONCY) is a publicly traded Healthcare sector company. As of May 21, 2026, ONCY trades at $0.84 with a market cap of $92.91M and a P/E ratio of -2.77. ONCY moved +6.72% today. Year to date, ONCY is -15.03%; over the trailing twelve months it is +90.83%. Its 52-week range spans $0.33 to $1.53. Analyst consensus is strong buy with an average price target of $6.00. Rallies surfaces ONCY's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
Oncolytics' Pelareorep Yields 19.5-Month Median Response in KRAS-Mutant MSS Colorectal Cancer: Pelareorep-based therapy achieved a 19.5-month median duration of response in second-line KRAS-mutant MSS colorectal cancer, compared with a 4–6 month historical benchmark. The combination also produced a 33% objective response rate versus 6–11% standard therapy, and the company is engaging FDA on an accelerated approval path.
| Metric | Value |
|---|---|
| Price | $0.84 |
| Market Cap | $92.91M |
| P/E Ratio | -2.77 |
| EPS | $-0.30 |
| Dividend Yield | 0.00% |
| 52-Week High | $1.53 |
| 52-Week Low | $0.33 |
| Volume | 147 |
| Avg Volume | 0 |
| Revenue (TTM) | $0 |
| Net Income | $-28.76M |
| Gross Margin | 0.00% |
4 analysts cover ONCY: 0 strong buy, 3 buy, 1 hold, 0 sell, 0 strong sell. Consensus rating is strong buy. Average price target: $6.00.